if the strategy is not released pre AGM then we are
likely waiting on FTO - ASH data. I think this is very plausible.
if the proposed strategy is mBC biomarker and post approval CDx then FTO data is critical.
Option 1, they are so confident they release any. Way without the data.
Option 2, wait until data is released to ensure no revision of the strategy.
Whats worse, revising the strategy again, or, delaying and getting it right?
Ann: Letter to Shareholders, Notice of AGM & Proxy Form, page-50
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |